MARKET WIRE NEWS

Fidelity Freedom 2065 Fund Q4 2024 Review

Source: SeekingAlpha

2025-03-18 08:00:00 ET

Summary

  • The fourth quarter of 2024 was volatile for most asset classes against a backdrop of the U.S. election, surging dollar strength, sticky inflation and rising interest rates in some markets.
  • Active asset allocation decisions detracted from the Fund's performance versus the Fidelity Freedom® 2030 Composite Index in Q4, whereas the investment performance of the underlying portfolios contributed.
  • Most underlying building-block portfolios across all asset classes outperformed or performed roughly in-line with their respective benchmark for the quarter.
  • Active risk relative to the Composite index is at the low end of our historical range. The Fund is overweight equities, with a preference for non-U.S. relative to U.S. equities.

Performance Summary

Cumulative Annualized
3 1 3 5 10 Year/ LOF1
Month YTD Year Year Year
Fidelity Freedom 2065 Fund Gross Expense Ratio: 0.76%2 -2.38% 14.02% 14.02% 3.95% 9.09% 9.94%
S&P 500 Index 2.41% 25.02% 25.02% 8.94% 14.53% 15.27%
Fidelity Freedom 2065 Composite Index -1.87% 14.40% 14.40% 3.99% 8.77% 9.58%
Morningstar Fund Target-Date 2065+ -1.85% 14.48% 14.48% 4.15% 8.90% --
% Rank in Morningstar Category (1% = Best) -- -- 69% 55% 40% --
# of Funds in Morningstar Category -- -- 193 147 43 --

Read the full article on Seeking Alpha

For further details see:

Fidelity Freedom 2065 Fund Q4 2024 Review
CVS Health Corporation

NASDAQ: CVS

CVS Trading

-2.04% G/L:

$75.86 Last:

1,964,123 Volume:

$76 Open:

mwn-ir Ad 300

CVS Latest News

CVS Stock Data

$95,397,851,248
1,255,468,728
N/A
1076
N/A
Medical Service Plans
Healthcare
US
Woonsocket

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App